AgingResearch.NewsJoin free

Biomea Fusion

CompanyUnited States

Biomea Fusion develops one asset, in human trials (icovamenib in type 1 diabetes). Mostly small molecule acting on MEN1; based in the United States.

1
Asset
Furthest stage
Human trials
Raised
US$81m
0
Trials
1
Signal

Pipeline

1

  • icovamenib

    Covalently inhibits menin, promoting pancreatic beta cell proliferation and enhancing GLP-1 receptor expression and insulin content.

    Human trials, Small molecule, MEN1, type 1 diabetes, type 2 diabetes

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Funding rounds and grants2
  • Signals2
  • Similar companies6

Papers

Intelligence